Therapies for COVID-19 mild to moderate disease are guided by the state guideline based on PBS requirements and national guidelines.
Please note that these state guidelines are updated regularly.
For patients to be considered for COVID-19 treatments, the referral must include:
the indication for the specific therapy
list of other medical conditions
current medications with their indications and doses, and
most recent renal function (including date).
COVID-19 Virtual ward
In scope
Adult Patient who:
has been assessed by a medical practitioner AND
has a positive test (PCR or RAT) AND
meets eligibility criteria for injectable COVID-19 Outpatient therapies that cannot be provided for by the General Practitioner (currently this is only if patient meets criteria for remdesivir as there are no other injectable or hospital only therapies for COVID-19 currently being prescribed.
Out of scope
Referral for COVID monitoring
Severe COVID symptoms – patients should be referred to the Emergency Department
Patients with contraindications to the injectable therapies
Referral Templates (please ensure you have downloaded most current version)
Virtual Ward referrals should only be sent using Medical Objects or via fax 07 5687 0096.
Dedicated GP only support
GP COVID Support Line – Support for GPs to navigate patient and system queries related to COVID.
Phone 5687 0003, Monday to Friday 8am – 5pm
Emergency Department fax – Fax patient information for any referrals to Emergency Department Fax 5687 4699
Severe Symptoms
At any time, if a patient has Red Flag symptoms (such as new or worsening breathlessness, chest pain or tightness) call 000 and ensure they are advised the person is (is likely) COVID-19 positive. Please refer to the RACGP COVID-19 Home Care Guidelines for as full list of “Red Flag” symptoms.
National COVID-19 Clinical Evidence Taskforce guidelines and clinical flowcharts for the care of people with post–COVID-19 and local HealthPathways, acknowledging that uncertainties remain in our understanding of the sequelae of COVID-19 and its management.